Abstract Number: 1456 • ACR Convergence 2023
Systematic Review of Effects of Systemic Lupus Erythematosus on Brain Structure and Structural Connectivity and Its Relationship with Cognitive Dysfunction Through an Advanced Neuroimaging Lens
Background/Purpose: Cognitive dysfunction (CD) is highly prevalent in systemic lupus erythematosus (SLE), and advanced structural magnetic resonance imaging (MRI) has revealed brain abnormalities in patients…Abstract Number: 1461 • ACR Convergence 2023
Association of Serum Analytes with SLE Cognitive Impairment Phenotypes Formed by Machine Learning: MMP-9, S100A8/A9, IL-6, IL-10, and NGAL
Background/Purpose: Cognitive impairment (CI) is highly prevalent in patients with SLE [prevalence of 38% (range: 20%-80%)]. The exact mechanisms underlying CI is complex and multifactorial.…Abstract Number: 1463 • ACR Convergence 2023
Predictors of Cognitive Impairment in Individuals with Systemic Lupus Erythematosus
Background/Purpose: The purpose of this study was to investigate factors associated with objective cognitive impairment in patients diagnosed with Systemic Lupus Erythematous (SLE). Subjective complaints…Abstract Number: 041 • 2023 Pediatric Rheumatology Symposium
Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort
Background/Purpose: The PedAnam (Pediatric Automated Neuropsychological Assessment Metrics) is an automatic software to evaluate cognitive performance that has recently been validated into Portugues (Brazil). The…Abstract Number: 0062 • ACR Convergence 2022
Comparing Alzheimer’s Disease Risk in Patients with Chronic Inflammatory Autoimmune Diseases: A Medicare Cohort Study
Background/Purpose: Chronic inflammatory diseases have been associated with an increased risk of Alzheimer’s disease (AD), yet emerging research in rheumatoid arthritis (RA) and psoriasis suggests…Abstract Number: 1708 • ACR Convergence 2022
A Role for the RAGE Receptor in Chronic Neurotoxicity After Exposure to SLE Antibodies That Cross React with dsDNA and the NMDA Receptor
Background/Purpose: Neurologic dysfunction occurs in up to 80% of SLE patients. Cognitive impairment is one of the most frequent manifestations of neuropsychiatric SLE (NPSLE). There…Abstract Number: 0322 • ACR Convergence 2022
Are Virtual Cognitive Assessments Comparable to In-person Assessments in a Systemic Lupus Erythematosus Cohort?
Background/Purpose: Many in-person research studies, such as ours examining cognitive impairment (CI) in SLE, were paused for safety reasons during the COVID-19 pandemic. To restart…Abstract Number: 1754 • ACR Convergence 2022
Association of Cognitive Impairment and Symptomatic Lower Extremity Osteoarthritis by Level of Physical Activity: Preliminary Data from the Johnston County Health Study
Background/Purpose: While osteoarthritis (OA) is associated with an increased risk of dementia,1 the frequency of milder cognitive impairment is unknown. Mild to moderate cognitive impairment…Abstract Number: 0330 • ACR Convergence 2022
Assessing the Utility of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Impairment in Patients with SLE Using a Bayesian Item-Response Theory Model
Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric syndromes in patients with SLE, with a prevalence ranging from 20% to…Abstract Number: 2058 • ACR Convergence 2022
Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
Background/Purpose: Cognitive impairment (CI) is prevalent in SLE and negatively impacts social and occupational engagement. There is a need for a patient-reported outcome measure (PROM)…Abstract Number: 0363 • ACR Convergence 2022
Centrally-Acting Angiotensin Converting Enzyme Inhibitor (cACEi) and Angiotensin Receptor Blocker (cARB) Use and Cognitive Dysfunction in Patients with Systemic Lupus
Background/Purpose: Cognitive dysfunction (CD) is detectable in 40% of patients with systemic lupus erythematosus (SLE). Despite this high prevalence, there are limited treatment options for…Abstract Number: 2074 • ACR Convergence 2022
Poor Executive Function Correlates with Increased Disease Damage and Impaired Patient-Reported Outcomes in Youth with Childhood-Onset Lupus: A Cross-Sectional Study
Background/Purpose: Cognitive dysfunction affects up to 60% of youth with childhood-onset systemic lupus erythematosus (cSLE), particularly executive dysfunction (ED), with adverse effects on treatment adherence,…Abstract Number: 0517 • ACR Convergence 2022
Cortical Surface Area Correlates with Cognitive Efficiency and Disease Measures in Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Cognitive difficulties are common in children with childhood-onset SLE (cSLE), but neuropsychiatric lupus (NPSLE) remains challenging to diagnose and treat. To increase understanding of…Abstract Number: 0665 • ACR Convergence 2022
Screening for Neurocognitive Demands in Childhood-onset Systemic Lupus Erythematosus Patients Using Pediatric Automated Neuropsychological Assessment Metrics and Association with Magnetic Resonance Imaging
Background/Purpose: Neuropsychiatric manifestations are frequently seen in patients with childhood-onset erythematosus (cSLE) and may include neurocognitive dysfunction. These symptoms are difficult to diagnose and classify…Abstract Number: 0793 • ACR Convergence 2022
Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation
Background/Purpose: Up to 70% of the 236 million people who have been diagnosed with SARS-CoV-2 develop post-COVID symptoms. (1) This has been defined by the…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 9
- Next Page »